Yuhan Corp - Company Profile
Powered by 
All the data and insights you need on Yuhan Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date Yuhan Corp Strategy Report
- Understand Yuhan Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Yuhan Corp (Yuhan) discovers, develops, manufactures and markets pharmaceutical products. The company offers APIs and intermediates for antibiotic, antiviral, antifungal, anti-thrombotic, anti-inflammatory, anti-diabetic and anti-hyperlipidemics. The company offers finished goods for the treatment of hypertension, coronary artery disease, hyperlipidemia, cerebral thrombosis and other diseases. Yuhan provides custom synthesis services for other pharmaceutical and biopharmaceutical companies. It offers active pharmaceutical ingredients (API) and finished products in domestic as well as international market. Yuhan operates R&D and manufacturing facilities in Seoul. The company offers its products and services through its sales and distribution branches. Yuhan is headquartered in Seoul, South Korea.
Headquarters
South Korea
Address
74, Noryangjin-Ro, Dongjak-Gu, Seoul, 06927
Website
www.yuhan.co.kr
Telephone
82 2 8280181
No of Employees
1,594
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
000100 (KRX)
Revenue (2022)
$1.4B
4.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
43%
(2022 vs 2021)
Market Cap*
$4.1B
Net Profit Margin (2022)
XYZ
36.6%
(2022 vs 2021)
* As of and is in US$
Yuhan Corp premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| APIs & Intermediates: | Custom Synthesis Service | - |
| Levofloxacin Hemihydrate | Supply Chain Management | Viread |
| Piperacillin Monohydrate | Trajenta | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In April, the company entered into an agreement with Aigen Sciences to identify a new artificial intelligence-based anticancer drug's mechanism of action. |
| 2023 | Acquisitions/Mergers/Takeovers | In October, the company acquired a 42% stake in ImmuneOncia Therapeutics Inc. |
| 2023 | Contracts/Agreements | In April, the company entered into an agreement to acquire 38.9% stake in Progen. |
Competitor Comparison
| Key Parameters | Yuhan Corp | GC Corp | Daewoong Pharmaceutical Co Ltd | Huons Global Co Ltd | Yuyu Pharma Inc |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Seoul | Yongin | Hwaseong | Seongnam | Jecheon |
| State/Province | - | - | - | - | Seoul |
| No. of Employees | 1,594 | 170 | 1,256 | 541 | 243 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Wook Je Cho | Chief Executive Officer; President | Executive Board | 2021 | 68 |
| Jung Hee Lee | Chairman | Non Executive Board | 2021 | 72 |
| Seong su Kim | Director; Manager- Life & Health Business | Executive Board | 2021 | 58 |
| Yoo Jae -cheon | Managing Director; Head- Pharmaceutical Business Division | Executive Board | - | 55 |
| Park Eun- hee | Head- Legal Office; Director | Executive Board | - | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward